128 related articles for article (PubMed ID: 18826857)
1. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study.
Fadem SZ; Al-Saghir F; Zollner G; Swan S
Clin Nephrol; 2008 Oct; 70(4):319-24. PubMed ID: 18826857
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
Zisman AL; Ghantous W; Schinleber P; Roberts L; Sprague SM
Am J Nephrol; 2005; 25(6):591-5. PubMed ID: 16282676
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
4. Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.
Kant KS; Gonzalez AR; Hariachar S; Bernardo M; Duggal A; Engstrand S; Hunter J; Plone M; Hertel J
J Ren Nutr; 2012 Jan; 22(1):34-40.e2. PubMed ID: 21652220
[TBL] [Abstract][Full Text] [Related]
5. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Joist HE; Ahya SN; Giles K; Norwood K; Slatopolsky E; Coyne DW
Clin Nephrol; 2006 May; 65(5):335-41. PubMed ID: 16724654
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Staniforth ME; Cheng SC; Coyne DW
Clin Nephrol; 2005 Jun; 63(6):454-60. PubMed ID: 15960147
[TBL] [Abstract][Full Text] [Related]
9. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
10. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
11. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
12. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
Martin KJ; González EA; Gellens M; Hamm LL; Abboud H; Lindberg J
J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
[TBL] [Abstract][Full Text] [Related]
13. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
[TBL] [Abstract][Full Text] [Related]
14. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
15. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
Llach F; Keshav G; Goldblat MV; Lindberg JS; Sadler R; Delmez J; Arruda J; Lau A; Slatopolsky E
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S48-54. PubMed ID: 9808143
[TBL] [Abstract][Full Text] [Related]
16. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
[TBL] [Abstract][Full Text] [Related]
17. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
18. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
Koc H; Hoser H; Akdag Y; Kendir C; Ersoy FF
Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
[TBL] [Abstract][Full Text] [Related]
19. Use of 3-hour daily hemodialysis and paricalcitol in patients with severe secondary hyperparathyroidism: A case series.
Achinger SG; Mizani MR; Ayus JC
Hemodial Int; 2010 Apr; 14(2):193-9. PubMed ID: 20337743
[TBL] [Abstract][Full Text] [Related]
20. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
